NEET 1992.

Study characteristics
Methods	Trial design: Multi‐centre, parallel, randomised, double‐blind, double‐dummy study
Participants	Participants: 315 women were randomised, 307 were analysed for safety and 263 were analysed for efficacy. Mean age: not stated  Inclusion criteria:  Laparoscopically diagnosed endometriosis 18‐45 years old  Not pregnant  Pap smear negative for malignancy  Normal menstrual cycle 21‐36 days for previous 4 months  Weight between 45‐110 kg  Exclusion criteria:  Amenorrhoea  Concurrent disease which may interfere with endometriosis or contraindicate the use of androgenic therapy  Surgical treatment at baseline or within 6 months prior to study  Use of danazol, androgenic hormones, oestrogens, or progestogens within 3 months prior to study  Setting: Multiple sites within Europe  Timing: not stated
Interventions	Nafarelin 200 mcg twice daily intranasal + placebo per os for 6 months (n = 206)  versus  Danazol 200 mg three times a day per os + placebo intranasal for 6 months (n = 101)
Outcomes	Relief of overall pain: dysmenorrhoea, dyspareunia, pelvic pain, pelvic tenderness and induration  Adverse effects AFS score
Notes	Intention‐to‐treat analysis: no Sample size calculation:  not stated Funding: Supported in part by Syntex Research, Palo Alto, California, US Note previous version: 8 participants who were randomised never took the study medication.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"patients were randomised so that 2 were assigned to receive nafarelin for every 1 assigned to receive danazol". No further information was provided on method used to generate random sequence.
Allocation concealment (selection bias)	Unclear risk	No details were provided of method used to conceal treatment group allocation.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind study
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double‐blind study
Incomplete outcome data (attrition bias) All outcomes	Low risk	Detail for attrition:  "307 were included in the safety analyses, of whom 263 also qualified for the efficacy analyses (171 nafarelin and 92 danazol recipients)"  25 had been treated < 150 days  7 were treated > 150 days but refused or otherwise missed the post‐treatment laparoscopy  12 violated the study protocol  14 discontinued due to adverse events  4 for intercurrent illness  4 for personal reasons  1 due to ineffective treatment  2 lost to follow‐up
Selective reporting (reporting bias)	Low risk	The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were prespecified.
Other bias	Low risk	No other risk of bias detected